SEARCH

SEARCH BY CITATION

References

  • 1
    Argiles JM, Almendro V, Busquets S, Lopez-Soriano FJ. The pharmacological treatment of cachexia. Curr Drug Targets 2004; 5: 26577.
  • 2
    Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO, Jr., Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980; 69: 4917.
  • 3
    Warren S. The immediate causes of death in cancer. Am J Med Sci 1932; 184: 6105.
  • 4
    Tayek JA. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 1992; 11: 44556.
  • 5
    Rohdenburg GL, Bernhard A, Krehbiel O. Sugar tolerance in cancer. J Am Med Assoc 1919; 72: 52830.
  • 6
    Beck SA, Tisdale MJ. Effect of insulin on weight loss and tumour growth in a cachexia model. Br J Cancer 1989; 59: 67781.
  • 7
    Lazarus DD, Kambayashi T, Lowry S, Strassmann G. The lack of an effect by insulin or insulin-like growth factor-1 in attenuating colon-2-mediated cancer cachexia. Cancer Lett 1996; 103: 717.
  • 8
    Moley JF, Morrison SD, Norton JA. Insulin reversal of cancer cachexia in rats. Cancer Res 1985; 45: 492531.
  • 9
    Moley JF, Morrison SD, Norton JA. Preoperative insulin reverses cachexia and decreases mortality in tumor-bearing rats. J Surg Res 1987; 43: 218.
  • 10
    Moley JF, Morrison SD, Gorschboth CM, Norton JA. Body composition changes in rats with experimental cancer cachexia: improvement with exogenous insulin. Cancer Res 1988; 48: 27847.
  • 11
    Peacock JL, Norton JA. Impact of insulin on survival of cachectic tumor-bearing rats. J Parenter Enteral Nutr 1988; 12: 2604.
  • 12
    Vona-Davis L, Howard-McNatt M, Rose D. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 2007; 8: 395408.
  • 13
    Goodwin P, Ennis M, Pritchard K, Trudeau M, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2001; 20: 4251.
  • 14
    Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen P, Gaziano J, Pollak M, Stampfer M. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008; 9: 103947.
  • 15
    Cersosimo E, Pisters PW, Pesola G, Rogatko A, Vydelingum NA, Bajorunas D, Brennan MF. The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia. Surgery 1991; 109: 45967.
  • 16
    Dodesini AR, Benedini S, Terruzzi I, Sereni LP, Luzi L. Protein, glucose and lipid metabolism in the cancer cachexia: A preliminary report. Acta Oncol 2007; 46: 11820.
  • 17
    Wolever TM, Jenkins DJ, Jenkins AL, Josse RG. The glycemic index: methodology and clinical implications. Am J Clin Nutr 1991; 54: 84654.
  • 18
    Acharyya S, Butchbach ME, Sahenk Z, Wang H, Saji M, Carathers M, Ringel MD, Skipworth RJ, Fearon KC, Hollingsworth MA, Muscarella P, Burghes AH, et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 2005; 8: 42132.
  • 19
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 4028.
  • 20
    Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del PP, Burden SJ, Di LR, Sandri C, Zhao J, Goldberg AL, Schiaffino S, et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 2007; 6: 45871.
  • 21
    Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399412.
  • 22
    Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva T, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004; 14: 395403.
  • 23
    Wendel AA, Purushotham A, Liu LF, Belury MA. Conjugated linoleic acid fails to worsen insulin resistance but induces hepatic steatosis in the presence of leptin in ob/ob mice. J Lipid Res 2008; 49: 98106.
  • 24
    Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 2006; 83: 134550.
  • 25
    Tanaka Y, Eda H, Tanaka T, Udagawa T, Ishikawa T, Horii I, Ishitsuka H, Kataoka T, Taguchi T. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res 1990; 50: 22905.
  • 26
    Ryall JG, Lynch GS. The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting. Pharmacol Ther 2008; 120: 21932.
  • 27
    Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005; 123: 9939.
  • 28
    Guerre-Millo M. Adiponectin: an update. Diabetes Metab 2008; 34: 128.
  • 29
    Musi N, Goodyear LJ. Insulin resistance and improvements in signal transduction. Endocrine 2006; 29: 7380.
  • 30
    Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A 2001; 98: 144405.
  • 31
    Proud CG. Regulation of protein synthesis by insulin. Biochem Soc Trans 2006; 34: 2136.
  • 32
    Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, Guttridge DC. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004; 114: 3708.
  • 33
    Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 2001; 11: 7648.
  • 34
    Kim KY, Cho HS, Jung WH, Kim SS, Cheon HG. Phosphatase and tensin homolog deleted on chromosome 10 suppression is an important process in peroxisome proliferator-activated receptor-gamma signaling in adipocytes and myotubes. Mol Pharmacol 2007; 71: 155462.